Page last updated: 2024-08-23

zidovudine and Pancreatic Neoplasms

zidovudine has been researched along with Pancreatic Neoplasms in 5 studies

Research

Studies (5)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's4 (80.00)18.2507
2000's0 (0.00)29.6817
2010's1 (20.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Hoshino, T; Kodama, R; Mizushima, T; Moritomo, S; Namba, T1
Chandrasekaran, B; Duch, DS; Kute, TE1
Ansari, R; Gonin, R; Loehrer, PJ; McClean, J; Miller, KD; Mortimer, J; Pletcher, W; Spiridonidis, CH; Weber, G1
Taniki, T; Weber, G; Zhen, YS1
Nagai, M; Nakamura, H; Olah, E; Prajda, N; Szekeres, T; Weber, G1

Trials

1 trial(s) available for zidovudine and Pancreatic Neoplasms

ArticleYear
A phase II study of weekly oral methotrexate and zidovudine (AZT) in advanced adenocarcinoma of the pancreas and hepatocellular carcinoma.
    Investigational new drugs, 1996, Volume: 14, Issue:2

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Methotrexate; Middle Aged; Pancreatic Neoplasms; Remission Induction; Zidovudine

1996

Other Studies

4 other study(ies) available for zidovudine and Pancreatic Neoplasms

ArticleYear
Zidovudine, an anti-viral drug, resensitizes gemcitabine-resistant pancreatic cancer cells to gemcitabine by inhibition of the Akt-GSK3β-Snail pathway.
    Cell death & disease, 2015, Jun-25, Volume: 6

    Topics: Animals; Antimetabolites, Antineoplastic; Antiviral Agents; Apoptosis; Cell Line, Tumor; Cell Movement; Cell Survival; Deoxycytidine; Drug Resistance, Neoplasm; Equilibrative Nucleoside Transporter 1; Gemcitabine; Glycogen Synthase Kinase 3; Glycogen Synthase Kinase 3 beta; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Invasiveness; Pancreatic Neoplasms; Proto-Oncogene Proteins c-akt; RNA Interference; RNA, Small Interfering; Snail Family Transcription Factors; Transcription Factors; Up-Regulation; Xenograft Model Antitumor Assays; Zidovudine

2015
Synchronization of cells in the S phase of the cell cycle by 3'-azido-3'-deoxythymidine: implications for cell cytotoxicity.
    Cancer chemotherapy and pharmacology, 1995, Volume: 35, Issue:6

    Topics: Antineoplastic Agents; Breast Neoplasms; Carcinoma; Cell Division; Cell Survival; Colonic Neoplasms; Computer Simulation; DNA, Neoplasm; Drug Synergism; Flow Cytometry; Fluorouracil; Humans; Leukemia; Melanoma; Methotrexate; Pancreatic Neoplasms; S Phase; Tumor Cells, Cultured; Zidovudine

1995
Azidothymidine and dipyridamole as biochemical response modifiers: synergism with methotrexate and 5-fluorouracil in human colon and pancreatic carcinoma cells.
    Oncology research, 1992, Volume: 4, Issue:2

    Topics: Adenocarcinoma; Cell Division; Cell Line; Cell Survival; Colonic Neoplasms; Dipyridamole; DNA Replication; Drug Screening Assays, Antitumor; Drug Synergism; Fluorouracil; Humans; Methotrexate; Pancreatic Neoplasms; Thymidine; Tumor Stem Cell Assay; Zidovudine

1992
AZT: a biochemical response modifier of methotrexate and 5-fluorouracil cytotoxicity in human ovarian and pancreatic carcinoma cells.
    Cancer communications, 1991, Volume: 3, Issue:4

    Topics: Animals; Binding, Competitive; Cell Line; Dose-Response Relationship, Drug; Drug Synergism; Female; Fluorouracil; Humans; Hypoxanthine; Hypoxanthines; In Vitro Techniques; Methotrexate; Ovarian Neoplasms; Pancreatic Neoplasms; Rats; Thymidine; Thymidine Kinase; Tumor Cells, Cultured; Zidovudine

1991